Medicinsk kombinationsbehandling af akromegali med somatostatinanalog og en vaeksthormon-receptorantagonist

Jens Otto Lunde Jørgensen; Ulla Feldt-Rasmussen; Jan Frystyk; Jian-Wen Chen; Lars Østergård Kristensen; Claus Hagen; Hans Ørskov

Medicinsk kombinationsbehandling af akromegali med somatostatinanalog og en vaeksthormon-receptorantagonist

Jens Otto Lunde Jørgensen, Ulla Feldt-Rasmussen, Jan Frystyk, Jian-Wen Chen, Lars Østergård Kristensen, Claus Hagen, Hans Ørskov

Abstract

We tested the effect of co-treatment of acromegaly with a somatostatin analogue (SA) and a growth hormone receptor antagonist (GHA). Eleven patients underwent: 1) conventional treatment with SA, 2) discontinued treatment, 3) 6 weeks treatment with GHA (10 mg), 4) 6 weeks treatment with GHA (15 mg), 5) 3 months combined SA and GHA. Circulating IGF-I was lowered by GHA and more so with combined treatment. Treatment with GHA increased endogenous GH levels, which was partly reversed by combined treatment. Plasma glucose levels were highest during SA treatment and lowest with GHA. Co-treatment of acromegaly with SA and GHA is a promising concept.

Bidragets oversatte titel	Medical co-treatment af acromegaly with a somatostatin analogue and a growth hormone receptor antagonist
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	169
Udgave nummer	10
Sider (fra-til)	911-3
Antal sider	3
ISSN	0041-5782
Status	Udgivet - 5 mar. 2007

Andre filer og links

https://ugeskriftet.dk/videnskab/medicinsk-kombinationsbehandling-af-akromegali-med-somatostatinanalog-og-en-vaeksthormon

Citationsformater

@article{ce00c3ac52364f6ca9835aaf46acdf25,

title = "Medicinsk kombinationsbehandling af akromegali med somatostatinanalog og en vaeksthormon-receptorantagonist",

abstract = "We tested the effect of co-treatment of acromegaly with a somatostatin analogue (SA) and a growth hormone receptor antagonist (GHA). Eleven patients underwent: 1) conventional treatment with SA, 2) discontinued treatment, 3) 6 weeks treatment with GHA (10 mg), 4) 6 weeks treatment with GHA (15 mg), 5) 3 months combined SA and GHA. Circulating IGF-I was lowered by GHA and more so with combined treatment. Treatment with GHA increased endogenous GH levels, which was partly reversed by combined treatment. Plasma glucose levels were highest during SA treatment and lowest with GHA. Co-treatment of acromegaly with SA and GHA is a promising concept.",

author = "J{\o}rgensen, {Jens Otto Lunde} and Ulla Feldt-Rasmussen and Jan Frystyk and Jian-Wen Chen and Kristensen, {Lars {\O}sterg{\aa}rd} and Claus Hagen and Hans {\O}rskov",

year = "2007",

month = mar,

day = "5",

language = "Dansk",

volume = "169",

pages = "911--3",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "10",

}

TY - JOUR

T1 - Medicinsk kombinationsbehandling af akromegali med somatostatinanalog og en vaeksthormon-receptorantagonist

AU - Jørgensen, Jens Otto Lunde

AU - Feldt-Rasmussen, Ulla

AU - Frystyk, Jan

AU - Chen, Jian-Wen

AU - Kristensen, Lars Østergård

AU - Hagen, Claus

AU - Ørskov, Hans

PY - 2007/3/5

Y1 - 2007/3/5

N2 - We tested the effect of co-treatment of acromegaly with a somatostatin analogue (SA) and a growth hormone receptor antagonist (GHA). Eleven patients underwent: 1) conventional treatment with SA, 2) discontinued treatment, 3) 6 weeks treatment with GHA (10 mg), 4) 6 weeks treatment with GHA (15 mg), 5) 3 months combined SA and GHA. Circulating IGF-I was lowered by GHA and more so with combined treatment. Treatment with GHA increased endogenous GH levels, which was partly reversed by combined treatment. Plasma glucose levels were highest during SA treatment and lowest with GHA. Co-treatment of acromegaly with SA and GHA is a promising concept.

AB - We tested the effect of co-treatment of acromegaly with a somatostatin analogue (SA) and a growth hormone receptor antagonist (GHA). Eleven patients underwent: 1) conventional treatment with SA, 2) discontinued treatment, 3) 6 weeks treatment with GHA (10 mg), 4) 6 weeks treatment with GHA (15 mg), 5) 3 months combined SA and GHA. Circulating IGF-I was lowered by GHA and more so with combined treatment. Treatment with GHA increased endogenous GH levels, which was partly reversed by combined treatment. Plasma glucose levels were highest during SA treatment and lowest with GHA. Co-treatment of acromegaly with SA and GHA is a promising concept.

UR - https://ugeskriftet.dk/videnskab/medicinsk-kombinationsbehandling-af-akromegali-med-somatostatinanalog-og-en-vaeksthormon

M3 - Tidsskriftartikel

C2 - 17359735

SN - 0041-5782

VL - 169

SP - 911

EP - 913

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 10

ER -

Medicinsk kombinationsbehandling af akromegali med somatostatinanalog og en vaeksthormon-receptorantagonist

Abstract

Andre filer og links

Fingeraftryk

Citationsformater